Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
Kenneth AlgazyJuly 3, 2008
Lung cancer profiling- May lead to improvements in care! Implications for Genentech & others.
Analysis of: Detection of Mutations in EGFR in Circulating Lung-Cancer Cells | content.nejm.org
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
We may be able to analyze EGFR mutations from periperal blood of lung cancer patients. Very frequently enough tissue fromm needle biopsies are not available for analysis. This may replace the need for new biopsies.
Kenneth AlgazyJuly 3, 2008
Amgen/Oral VEGF Inhibitor/Implications??? Interesting future!
Analysis of: Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer | content.nejm.org
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
This oral Vascular Endothelial Growth Factor (VEGF) inhibitor appears to have activity in radioresistant differentiated thyroid carcinoma.
Kenneth AlgazyJune 30, 2008
The heck with the impact on Roche. How about the patients??
Analysis of: Roche decision denies cancer drug to Britons | www.ft.com
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Patients who wish to receive Avastin for breast and lung Cancer will need to pay for it themselves.
Kenneth AlgazyJune 30, 2008
How are we to pay for computers with a 10% drop in Medicare fees?
Analysis of: Medicare fees to doctors fall Tuesday | news.yahoo.com
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Rising costs for care of seniors in physician offices will be made more painful by the reimbursement cuts. Will it impede care of seniors??
Kenneth AlgazyJune 27, 2008
The other shoe falls II: Amgen and J & J will not be happy.
Analysis of: Europe Backs Anemia-Drug Warnings | online.wsj.com
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Due to possible tumor growth warnings will be attached to the use of erythropoietin agents.
Kenneth AlgazyJune 26, 2008
Bayer and J &J in the propylactic anticoagulation market. GSK (Lovenox) beware!
Analysis of: Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty | content.nejm.org
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
This paper as well as http://content.nejm.org/cgi/content/full/358/26/2765 report the efficacy of an oral anticoagulant type drug that appears to be better & safer than parenteral low molecular weight heparin (LMWH).
June 24, 2008
Molecular Profiling for Epo Stimulating Agents: Trying to 'Stop the Bleeding'
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents | www.medscape.com
Author: GLG Expert Contributor
Use of Epo Stimulating Agents (ESAs) for cancer patients have all but come to a screeching halt when a plattoon of studies came out suggesting that ESAs might actually cause more harm, notably by possibly acting as a growth factor for tumor cells.  Now, reserachers are trying to determine...
Kenneth AlgazyJune 23, 2008
Amgen as well as J & J: Adding insult to injury......
Analysis of: New Study Probes Safety of Erythropoiesis-Stimulating Agents | www.medscape.com
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Safety concerns continue to be voiced re: the effect of erythropoietin products (Epos) on tumor growth.
Kenneth AlgazyJune 20, 2008
Electronic Records?? Great but.......
Analysis of: Most Doctors Aren’t Using Electronic Health Records | www.nytimes.com
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Only 1 in 5 physicians use electronic patient records. ( and those are either in University Hospitals, large multispecialty clinics or VA hospitals)
Kenneth AlgazyJune 19, 2008
GSK is going after Genentech's (Herceptin) Cookies....
Analysis of: Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer | jco.ascopubs.org
Author: Kenneth Algazy, Clinical Professor of Medicine , University of Pennsylvania School of Medicine - CC
Lapatinib, an oral HER-2 inhibitor, is effective in monotherapy in HER-2+ metastatic breast cancer.

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 393

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics